References
- Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–1720.
- Sohrabi C, Alsafi Z, O’Neill N, et al. World health organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020 Apr 1;76:71–76.
- WHO. Coronavirus disease (COVID-19) pandemic. Internet]. 2020 [cited 2020 Jul 5]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus–2019.
- Wu Z, McGoogan JM Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA [Internet]. 2020 Feb 24 [cited 2020 Jun 24]; Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020 [cited 2020 Jun 24];395:497–506. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext.
- Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Apr 23;525(1):135–140.
- Letko M, Marzi A, Munster V Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020 Apr 1;5(4):562–569.
- Melenotte C, Silvin A, Goubet AG, et al. Immune responses during COVID-19 infection. Oncoimmunology. 2020 Aug 25;9(1):1807836. PMID: 32939324; PMCID: PMC7480812.
- Pedersen SF, Ho YC SARS-CoV-2: A storm is raging. J Clin Investigat Am Soc Clin Investigat. 2020;130:2202–2205.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China [published online ahead of print, 2020 Mar 12]. Clin Infect Dis 2020;ciaa248. doi:https://doi.org/10.1093/cid/ciaa248.
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. Published 2020 Mar 18.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. DOI: https://doi.org/10.1093/cid/ciaa237
- US President’s tweet [Internet]. 2020 [cited 2020 Jun 24]. Available from: https://twitter.com/realDonaldTrump/status/1241367239900778501?s=20
- Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine [Internet]. FDA. 2020 [cited 2020 Jun 20]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
- WHO suspends hydroxychloroquine study over safety concerns [Internet]. Time. [cited 2020 Jun 20]. Available from: https://time.com/5842264/hydroxychloroquine-testing-who/
- WHO resumes study of hydroxychloroquine for treating COVID-19 [Internet]. Time. [cited 2020 Jun 20]. Available from: https://time.com/5847664/who-hydroxychloroquine-covid–19/
- WHO halts trial of hydroxychloroquine in COVID-19 patients. Reuters [Internet]. [cited 2020 Jun 28]. Available from: https://in.reuters.com/article/us-health-coronavirus-who-hydroxychloroq-idINKBN23O2T0
- Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents 2020;105949. doi:https://doi.org/10.1016/j.ijantimicag.2020.105949.
- Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020 Mar 1;34:101663.
- Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020 May 5;101738.
- Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19(published pre-proof). Inter J Infect Dis [Internet]. 2020. PII: S1201-9712(20)30534-8. [cited 2020 July 4]. DOI: https://doi.org/10.1016/j.ijid.2020.06.099
- Drug interactions checker - medscape drug reference database [Internet]. [cited 2020 Jul 5]. Available from: https://reference.medscape.com/drug-interactionchecker
- Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020 Jun;26(6):808–809.
- Choi Y, Lim HS, Chung D, et al. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. BioMed Res Int 2018;2018:1574806.
- Gérard A, Romani S, Fresse A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French network of pharmacovigilance centers [published online ahead of print, 2020 May 7]. Therapie. 2020;S0040-5957(20)30091-3. DOI:https://doi.org/10.1016/j.therap.2020.05.002.
- Brogden RN, Speight TM, Avery GS Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs. 1975;9(4):251–291.
- Singh H, Kakkar AK, Chauhan P Repurposing minocycline for COVID-19 management: mechanisms, opportunities and challenges [published online ahead of print, 2020 Jun 17]. Expert Rev Anti Infect Ther. 2020;. doi:https://doi.org/10.1080/14787210.2020.1782190.
- Sodhi M, Etminan M Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy. 2020;40(5):487–488.
- Szeto GL, Pomerantz JL, Graham DR, et al. Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells. J Biol Chem. 2011;286(13):11275–11282.
- Garrido-Mesa N, Zarzuelo A, Gálvez J Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337–352.
- Kim HS, Suh YH Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168–179.
- Diana G, Strollo R, Diana D, et al. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management [published online ahead of print, 2020 May 7]. Eur Heart J Cardiovasc Pharmacother 2020;pvaa049. doi:https://doi.org/10.1093/ehjcvp/pvaa049.
- McChesney EW Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983 Jul 18;75(1 PART 1):11–18.
- Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–269.
- Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018 Aug 3;14(8):1435–1455.
- Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Jun 18 382(25):2411–2418.
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19 [published online ahead of print, 2020 Jun 3]. N Engl J Med 2020;NEJMoa2016638. doi:https://doi.org/10.1056/NEJMoa2016638.
- Statement from the chief investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) trial on hydroxychloroquine [Internet]. 2020 [cited 2020 Jul 4]. Available from: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf
- WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 [Internet]. 2020 [cited 2020 Jul 5]. Available from: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid–19
- Kaptein SJF, Jacobs S, Langendries L, et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. bioRxiv. Preprint posted online 19 June 2020. DOI: https://doi.org/10.1101/2020.06.19.159053.
- Park SJ, Yu KM, Kim YI, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio.2020;11. [PMID: 32444382] DOI:https://doi.org/10.1128/mBio.01114-20.
- Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. Research Square. Preprint posted online 6 May 2020 [cited 2020 Aug 24]. Available from: https://www.researchsquare.com/article/rs–27223/v1
- Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv. DOI:https://doi.org/10.1101/2020.07.15.20151852.
- Szeto GL, Brice AK, Yang H-C, et al. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis. 2010 Apr 15;201(8):1132–1140.
- Seabrook TJ, Jiang L, Maier M, et al. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006 May 53(7):776–782.
- Chen X, Ma X, Jiang Y, et al. The prospects of minocycline in multiple sclerosis. J Neuroimmunol. 2011;235(1–2):1–8.
- Phillips JM, Gallagher T, Weiss SR Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion. J Virol Mar 2017, 91 (8) e01564–16.
- Hanemaaijer R, Lent VN, Sorsa T, et al. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines. In: Nelson M, Hillen W, Greenwald RA, eds. Tetracyclines in biology, chemistry and medicine. Basel: Birkhäuser; 2001. pp 267-281. [Internet]. 2020 [cited 2020 Jul 5]; Available from: https://link.springer.com/chapter/10.1007/978-3-0348-8306-1_11
- Minocycline hydrochloride capsules (minocycline hydrochloride) dose, indications, adverse effects, interactions … from PDR.net [Internet]. [cited 2020 Jul 5]. Available from: https://www.pdr.net/drug-summary/Minocycline-Hydrochloride-Capsules-minocycline-hydrochloride–3396
- Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.
- Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol J Am Coll Cardiol. 2020 May, 75 (18) 2352–2371.
- Zhou X, Wang D, Ballard-Croft CK, et al. A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model. Ann Thorac Surg 2010 Aug 90(2):419–426.
- Roy SK, Kubiak BD, Albert SP, et al. Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury. Shock Augusta Ga. 2012 Apr;37(4):424–432.
- Sadowsky D, Nieman G, Barclay D, et al. Impact of chemically-modified tetracycline 3 on intertwined physiological, biochemical, and inflammatory networks in porcine sepsis/ARDS. Int J Burns Trauma. 2015 Mar 20;5(1):22–35.
- Roy SK, Kendrick D, Sadowitz BD, et al. Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). Pharmacol Res. 2011 Dec 1;64(6):580–589.
- Ge Y, Tian T, Huang S, et al. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv 2020 03 11 986836. DOI: https://doi.org/10.1101/2020.03.11.986836.
- Ahmad I, Alam M, Saadi R, et al. Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities. medRxiv 2020 05 18 20066902. DOI: https://doi.org/10.1101/2020.05.18.20066902.
- Bharadwaj S, Lee KE, Dwivedi VD, et al. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations [published online ahead of print, 2020 Jul 9]. Life Sci 2020;257:118080.
- Xiao B Minocycline might be an adjunctive therapy option for the treatment of COVID-19: in silico screening, structure-affinity relationship, and literature review. Preprint published Research square on 07 July, 2020. [cited 2020 Aug 24]. Available from: https://www.researchsquare.com/article/rs–40141/v1.
- NIH. Potential antiviral drugs under evaluation for the treatment of COVID-19. Antiviral Therapy [cited 2020 Jul 6]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/
- Assessment of evidence for COVID-19-related treatments: updated 4/3/2020. [cited 2020 Jul 5]. Available from: https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx?la=en&hash=B414CC64FD64E1AE8CA47AD753BA744EDF4FFB8C
- Maurin M, Benoliel AM, Bongrand P, et al. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 1992;166:1097–1102.
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18:41–58.
- Government of India. Ministry of health & family welfare directorate general of health services (EMR division). Revised guidelines on clinical management of COVID – 19. 31.03.2020. [Internet]. 2020 [cited 2020 Jun 24]; Available from: https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf.
- Clinical management protocol: COVID-19. Government of India ministry of health and family welfare directorate general of health services (EMR division) version 3, 13.06.20. [Internet]. 2020 [cited 2020 Jul 5]; Available from: https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf
- Hu X, Wu B, Wang X, et al. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol 2011;654:274–279.
- Plaquenil®. Hydroxychloroquine sulfate tablets, USP. [cited 2020 Jul 5]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
- Naghipour S, Ghodousi M, Rahsepar S, et al. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert Rev Anti Infect Ther. 2020 Jul 13:1–15. DOI: https://doi.org/10.1080/14787210.2020.1792291. Epub ahead of print. PMID: 32631083.
- Stremmel C, Kellnar A, Massberg S, et al. Hydroxychloroquine in COVID-19 therapy: protection versus proarrhythmia [published online ahead of print, 2020 Jul 23]. J Cardiovasc Pharmacol Ther 2020;1074248420935740. doi:https://doi.org/10.1177/1074248420935740.